S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|QIAGEN Announces Broad Agreement With Astellas Pharma to Develop Companion Diagnostics (2014/10/28)|
|Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan|
|Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy|
|Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer|
|Phase 3 PREVAIL Trial Named Clinical Advance of the Year by SCRIP|
|QIAGEN Reports Results for Third Quarter and First Nine Months of 2014 (2014/10/29)|
|Medivation Reports Third Quarter Financial Results and Provides Corporate Update|
|Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update|
|Innocoll AG Proposes Changes to Supervisory Board and Stock Option Plan|
|XenoPort to Release Third Quarter Financial Results on November 4|
Click above to view more mutual fund data and stats for alpmy - Astellas Pharma Inc ADR.